Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Research Inc

Neither a doctor nor a teaching hospital

Research payments

$600,341

97 payments

Through program year 2025, Research Inc is reported as receiving $600,341 in research payments, across 97 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $127,681 5
2024 Research $56,887 14
2023 Research $59,553 16
2022 Research $109,056 22
2021 Research $89,878 15
2020 Research $56,012 17
2019 Research $101,275 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $332,332 23 payments
  2. Amgen Inc. $78,646 4 payments
  3. Novartis Pharmaceuticals Corporation $59,417 1 payment
  4. Bayer HealthCare Pharmaceuticals Inc. $51,994 36 payments
  5. Gilead Sciences, Inc. $45,831 23 payments
  6. GlaxoSmithKline, LLC. $13,605 5 payments
  7. Lexicon Pharmaceuticals, Inc. $8,806 1 payment
  8. Grifols Therapeutics LLC $6,210 2 payments
  9. Eli Lilly and Company $2,000 1 payment
  10. Sanofi US Services Inc. $1,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma $154,788 7 payments
  2. VALOR-QI In Veterans with ASCVD $59,417 1 payment
  3. a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer $59,316 1 payment
  4. Galactic-Hf $54,625 1 payment
  5. A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) $37,497 3 payments
  6. BAY94-8862 LCM HFmr/pEF (EF 40%) $34,705 25 payments
  7. a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton $27,318 2 payments
  8. Forxiga HF-D1699C00001 HF rEF Outcome study $17,582 2 payments
  9. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $14,467 4 payments
  10. FOURIER OLE (Ph 4) $14,340 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record